权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Project 3: Targeting linear ubiquitination to attenuate inflammation and promote repair after viral pneumonia

项目3：靶向线性泛素化以减轻病毒性肺炎后的炎症并促进修复

基本信息

批准号：
10269676
负责人：
GR Scott Budinger
金额：
$ 54.4万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-15 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10269676
关键词：
2019-nCoV Acute Adult Respiratory Distress Syndrome Alveolar Alveolar Macrophages Antiviral Therapy Attenuated Cell physiology Cells Cessation of life Clinical Complex Data Development Enrollment Epithelial Epithelial Cells Failure Functional disorder Funding Opportunities Genes Genetic Transcription Heme Hypoxemia Infection Inflammation Inflammatory Inflammatory Response Influenza A virus Infrastructure Injury Instruction Interferon Type I Iron Regulatory Protein 2 Ligase Liquid substance Lung Measures Mediating Microbiology Molecular NF-kappa B Organ Outcome Paper Patients Phenotype Physiological Play Pneumonia Proteins Recovery Regulation Reporting Research Resolution Respiratory Failure Role Signal Transduction Supportive care Techniques Therapy trial Ubiquitin Ubiquitination Viral Pneumonia Virus Diseases alveolar epithelium community acquired pneumonia cytokine epithelial repair experimental study improved outcome individualized medicine injury and repair insight iron oxide lung injury lung repair macrophage monocyte mortality mouse model pathogen pneumonia treatment prevent repair function repaired response transcription factor ubiquitin ligase ubiquitin-protein ligase

项目摘要

In this PPG, all of the Projects and Cores consider the persistence of respiratory failure and the development of multiple organ dysfunction in patients with ARDS as a failure of normal mechanisms of inflammation resolution and lung repair. This hypothesis is clinically supported by a recent analysis of patients enrolled in the ARDSnet where a “hyerinflammatory” endotype of ARDS was associated with poor clinical outcomes including death. The expression of many genes encoding inflammatory cytokines is regulated by the transcription factor NF-B. Hence, understanding how NF-B activity is controlled over the course of lung injury and repair is likely to provide mechanistic insights into the pathobiology of successful or failed lung repair after injury. The Linear Ubiquitin Assembly Complex (LUBAC) is an E3 ubiquitin ligase that performs Met-1 ubiquitination necessary for NF-B activation. In preliminary experiments, we observed that epithelial specific deletion of a modulatory component of LUBAC (HOIL-1L) prevents NF-B signaling and improves outcomes in a murine model of influenza A virus infection. We present additional preliminary data that support our hypothesis that LUBAC promotes persistent NF-B signaling in the alveolar epithelium and monocyte-derived alveolar macrophages to inhibit lung repair after influenza A induced lung injury. Specific Aim 1. To determine whether inhibiting LUBAC-mediated NF-B activation in the lung epithelium during recovery from influenza A infection accelerates lung repair. We will perform timed experiments in which we will genetically inhibit LUBAC mediated NF-B signaling during recovery from influenza A infection and use complementary physiologic and molecular techniques to measure lung repair. Specific Aim 2. To determine whether activation of LUBAC mediated NF-B activation in the lung epithelium directs reparative phenotypes in monocyte-derived macrophages. We will determine whether the inflammatory phenotype of these cells is driven by the changing microenvironment—specifically the lung epithelium, or whether these changes are cell autonomous within the macrophage. Specific Aim 3. To determine whether increased expression of NF-B-dependent inflammatory genes in alveolar macrophages and BAL fluid from patients with severe pneumonia is associated with 30 day mortality. We will take advantage of the infrastructure provided by the Successful Clinical Response in Pneumonia Therapy (SCRIPT) trial to determine whether there is an association between the expression of NF- B target genes in alveolar macrophages and BAL fluid cytokines with clinical outcomes.

在本PPG中，所有的项目和核心都考虑了呼吸衰竭的持续存在和发展